BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27006491)

  • 1. Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.
    Thielen N; Richter J; Baldauf M; Barbany G; Fioretos T; Giles F; Gjertsen BT; Hochhaus A; Schuurhuis GJ; Sopper S; Stenke L; Thunberg S; Wolf D; Ossenkoppele G; Porkka K; Janssen J; Mustjoki S
    Clin Cancer Res; 2016 Aug; 22(16):4030-8. PubMed ID: 27006491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
    Defina M; Ippoliti M; Gozzetti A; Abruzzese E; Castagnetti F; Crupi R; Tiribelli M; Breccia M; Salvucci M; Aprile L; Baratè C; Gozzini A; Rosti G; Lauria F; Bocchia M
    Cancer; 2012 Nov; 118(21):5265-9. PubMed ID: 22517301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
    Pungolino E; D'adda M; De Canal G; Trojani A; Perego A; Elena C; Lunghi F; Turrini M; Borin L; Iurlo A; Latargia ML; Carraro MC; Spina F; Artale S; Anghilieri M; Molteni A; Caramella M; Baruzzo G; Nichelatti M; Di Camillo B; Cairoli R
    Eur J Haematol; 2021 Oct; 107(4):436-448. PubMed ID: 34139044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
    Mustjoki S; Richter J; Barbany G; Ehrencrona H; Fioretos T; Gedde-Dahl T; Gjertsen BT; Hovland R; Hernesniemi S; Josefsen D; Koskenvesa P; Dybedal I; Markevärn B; Olofsson T; Olsson-Strömberg U; Rapakko K; Thunberg S; Stenke L; Simonsson B; Porkka K; Hjorth-Hansen H;
    Leukemia; 2013 Jul; 27(7):1520-6. PubMed ID: 23328954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
    Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
    Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome.
    Fathy El-Metwaly N; Aref S; Ayed M; Abdel Hamid M; El-Sokkary AMA
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3237-3243. PubMed ID: 34711000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
    Berdeja JG; Heinrich MC; Dakhil SR; Goldberg SL; Wadleigh M; Kuriakose P; Cortes J; Radich J; Helton B; Rizzieri D; Paley C; Dautaj I; Mauro MJ
    Leuk Lymphoma; 2019 Oct; 60(10):2384-2393. PubMed ID: 30912699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.
    Janssen JJ; Deenik W; Smolders KG; van Kuijk BJ; Pouwels W; Kelder A; Cornelissen JJ; Schuurhuis GJ; Ossenkoppele GJ
    Leukemia; 2012 May; 26(5):977-84. PubMed ID: 22157734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Response in a Patient With CML Expressing
    Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
    In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
    Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.
    Sadovnik I; Hoelbl-Kovacic A; Herrmann H; Eisenwort G; Cerny-Reiterer S; Warsch W; Hoermann G; Greiner G; Blatt K; Peter B; Stefanzl G; Berger D; Bilban M; Herndlhofer S; Sill H; Sperr WR; Streubel B; Mannhalter C; Holyoake TL; Sexl V; Valent P
    Clin Cancer Res; 2016 Apr; 22(8):2051-61. PubMed ID: 26607600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 14. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
    Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
    Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
    Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.
    Valent P; Sadovnik I; Ráčil Z; Herrmann H; Blatt K; Cerny-Reiterer S; Eisenwort G; Lion T; Holyoake T; Mayer J
    Eur J Clin Invest; 2014 Dec; 44(12):1239-45. PubMed ID: 25371066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
    Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
    Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
    Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
    N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
    Willmann M; Sadovnik I; Eisenwort G; Entner M; Bernthaler T; Stefanzl G; Hadzijusufovic E; Berger D; Herrmann H; Hoermann G; Valent P; Rülicke T
    Exp Hematol; 2018 Jan; 57():50-59.e6. PubMed ID: 29031704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.